| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |